An Inside Look at Takeda Pharmaceutical Co. Ltd. and the Millenium Reorganization

Published: Jun 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Last month, Takeda Pharmaceuticals undertook yet another reorganization, but its latest effort to jumpstart operations held a surprise. Deborah Dunsire, who ran the autonomous Millenium Pharmaceuticals unit that the Japanese drugmaker purchased five years ago for $8.8 billion, resigned after it became clear the streamlining meant she would no longer be a ceo. And so, one of her long-time lieutenants, Anna Protopapas, 48, who has worked at Millennium for 16 years, most recently as executive vice president and head of global business development, replaced her and now runs the Takeda oncology operation in Cambridge, Massachusetts. The shift comes after the patent on the blockbuster Actos expired, exposing the need for Takeda to quickly bolster its pipeline and cut costs. We spoke with her about the changes and this is an edited version of the conversation…

Help employers find you! Check out all the jobs and post your resume.

Back to news